<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772495</url>
  </required_header>
  <id_info>
    <org_study_id>2015/7</org_study_id>
    <nct_id>NCT04772495</nct_id>
  </id_info>
  <brief_title>miRNA Biomarkers in Multiple Sclerosis</brief_title>
  <official_title>The Potential Candidate miRNA Biomarkers in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Gaziantep</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Gaziantep</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple Sclerosis (MS) characterized by demyelination and axonal degeneration is a chronic&#xD;
      inflammatory disease of the central nervous system (CNS). Recent studies have shown that&#xD;
      dysregulated miRNAs alter immune responses, so they may have roles basis on various genetic&#xD;
      diseases such as MS and may be potential targets for biomarkers and new therapeutic&#xD;
      approaches. In this study, we evaluated the dysregulation of miRNA expression levels at MS&#xD;
      and MS stages. We also discussed the potential of these miRNAs to be biomarkers and/or&#xD;
      therapeutic targets in MS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>miRNA expression</measure>
    <time_frame>intraoperative</time_frame>
    <description>peripheral blood miRNA expressions</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">69</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>miRNA</condition>
  <condition>Epigenetic</condition>
  <condition>Biomarker</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>with Multiple sclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>not Multiple sclerosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>miRNA</intervention_name>
    <description>miRNA effect on Multiple sclerosis pathology</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who had been diagnosed with Multiple sclerosis and healthy male and female&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The age of 25 years and above&#xD;
&#xD;
          -  at least one Central Nervous System (CNS) demyelination event&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  with genetic diseases, hypertension, head trauma, neuropsychiatric disease, diabetes&#xD;
             mellitus, hypertension, cardiac failure, hepatic failure, renal failure, Thalassemia,&#xD;
             Sickle cell disease, iron deficiency, and B12 deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Gaziantep</investigator_affiliation>
    <investigator_full_name>Şenay Görücü Yılmaz</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>miRNA biomarkers</keyword>
  <keyword>peripheral blood molecular diagnostics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

